/ABCL
ABCL Stock - AbCellera Biologics Inc.
Healthcare|BiotechnologyNASDAQ
$3.60+1.98%
+$0.07 (+1.98%) • Dec 19
72
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.35
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.91
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+408.1%upside
Target: $18.29
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ABCL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.56 – $3.64
TARGET (TP)$18.29
STOP LOSS$3.31
RISK/REWARD1:50.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.73
52W High$6.51
52W Low$1.89
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $28.83M | $38.02M | $485.42M | $375.20M | $233.16M |
| Gross Profit | $28.83M | $38.02M | $418.99M | $329.69M | $206.01M |
| Gross Margin | 100.0% | 100.0% | 86.3% | 87.9% | 88.4% |
| Operating Income | $-314,766,000 | $-237,207,000 | $216.51M | $204.41M | $156.03M |
| Net Income | $-162,857,000 | $-146,398,000 | $158.52M | $153.46M | $118.92M |
| Net Margin | -564.8% | -385.0% | 32.7% | 40.9% | 51.0% |
| EPS | $-0.55 | $-0.51 | $0.56 | $0.56 | $0.32 |
Company Overview
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
71%
Hold / Neutral
2
29%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
5 Bullish2 Neutral/Bearish
Price Targets
$15
Average Target
↑ 308.7% Upside
Now
$4
Low
$15
Average
$30
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 7th 2025 | Leerink Partners | Downgrade | Market Perform | $4 |
| July 7th 2025 | Leerink Partners | Resumed | Outperform | $5 |
| August 20th 2024 | The Benchmark Company | Downgrade | Hold | - |
| February 22nd 2024 | The Benchmark Company | Upgrade | Buy | $9 |
| December 5th 2023 | KeyBanc Capital Markets | Initiation | Overweight | $6 |
| November 6th 2023 | The Benchmark Company | Downgrade | Hold | - |
| October 13th 2023 | Piper Sandler | Resumed | Overweight | $20 |
| February 28th 2023 | Cowen | Initiation | Outperform | - |
| December 15th 2022 | Goldman | Initiation | Buy | $30 |
| November 16th 2022 | Truist | Initiation | Buy | $29 |
Earnings History & Surprises
ABCLBeat Rate
50%
Last 18 quarters
Avg Surprise
-102.0%
EPS vs Estimate
Beats / Misses
9/8
1 met exactly
Latest EPS
$-0.19
Q4 2025
EPS Surprise History
Q1 24
-21.4%
$-0.17vs$-0.14
Q2 24
+12.5%
$-0.14vs$-0.16
Q3 24
+13.3%
$-0.13vs$-0.15
Q4 24
-21.4%
$-0.17vs$-0.14
Q1 25
+26.7%
$-0.11vs$-0.15
Q2 25
+11.8%
$-0.15vs$-0.17
Q3 25
+29.4%
$-0.12vs$-0.17
Q4 25
-11.8%
$-0.19vs$-0.17
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-0.18 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.17 | $-0.19 | -11.8% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-0.17 | $-0.12 | +29.4% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.17 | $-0.15 | +11.8% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $-0.15 | $-0.11 | +26.7% | ✓ BEAT |
Q4 2024 | Nov 4, 2024 | $-0.14 | $-0.17 | -21.4% | ✗ MISS |
Q3 2024 | Aug 6, 2024 | $-0.15 | $-0.13 | +13.3% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $-0.16 | $-0.14 | +12.5% | ✓ BEAT |
Q1 2024 | Feb 20, 2024 | $-0.14 | $-0.17 | -21.4% | ✗ MISS |
Q4 2023 | Nov 2, 2023 | $-0.14 | $-0.10 | +28.6% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-0.13 | $-0.11 | +15.4% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $-0.12 | $-0.14 | -16.7% | ✗ MISS |
Q1 2023 | Feb 21, 2023 | $-0.01 | $-0.10 | -1804.8% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $0.05 | $0.08 | +60.0% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-0.02 | $-0.02 | -28.5% | ✗ MISS |
Q2 2022 | May 10, 2022 | $0.38 | $0.54 | +42.1% | ✓ BEAT |
Q1 2022 | Feb 24, 2022 | $0.19 | $0.19 | 0.0% | = MET |
Q4 2021 | Nov 9, 2021 | $-0.05 | $-0.08 | -60.0% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $0.09 | $-0.01 | -111.1% | ✗ MISS |
Latest News
AbCellera settles patent litigation with Bruker over microfluidic device tech
📈 PositiveSeeking Alpha•Dec 18, 2025, 02:57 PM•Also:
AbCellera Strikes Patent License Deal With Bruker; Bruker To Pay $36M As Future Royalty Payments On Sales Of Beacon Optofluidic Platform Globally
📈 PositiveBenzinga•Dec 18, 2025, 02:09 PM•Also:
Leerink Partners Downgrades AbCellera Biologics to Market Perform, Announces $4 Price Target
📉 NegativeBenzinga•Nov 7, 2025, 12:22 PM
AbCellera Biologics Q3 EPS $(0.19) Misses $(0.17) Estimate, Sales $8.955M Beat $5.909M Estimate
➖ NeutralBenzinga•Nov 6, 2025, 09:09 PM
AbCellera Doses First Participants In Phase 1 Clinical Trial Of ABCL575 For Treatment Of Moderate-To-Severe Atopic Dermatitis.
📈 PositiveBenzinga•Aug 27, 2025, 01:11 PM
Frequently Asked Questions about ABCL
What is ABCL's current stock price?
AbCellera Biologics Inc. (ABCL) is currently trading at $3.60 per share. The stock has moved +1.98% today.
What is the analyst price target for ABCL?
The average analyst price target for ABCL is $18.29, based on 1 analyst.
What sector is AbCellera Biologics Inc. in?
AbCellera Biologics Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ABCL's market cap?
AbCellera Biologics Inc. has a market capitalization of $1.08 billion, making it a small-cap company.
Does ABCL pay dividends?
No, AbCellera Biologics Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBHVN
Biohaven Ltd.
$10.85
Mkt Cap: $1.1B
CLDX
Celldex Therapeutics, Inc.
$25.60
Mkt Cap: $1.7B
IMNM
Immunome, Inc.
$21.44
Mkt Cap: $2.0B
JANX
Janux Therapeutics, Inc.
$13.79
Mkt Cap: $0.8B
NUVB
Nuvation Bio Inc.
$9.44
Mkt Cap: $3.2B
PHVS
Pharvaris N.V.
$25.59
Mkt Cap: $1.7B
SION
Sionna Therapeutics, Inc.
$42.37
Mkt Cap: $1.9B
SYRE
Spyre Therapeutics, Inc.
$33.40
Mkt Cap: $2.0B
VERA
Vera Therapeutics, Inc.
$51.22
Mkt Cap: $3.3B
XERS
Xeris Biopharma Holdings, Inc.
$7.34
Mkt Cap: $1.2B
Explore stocks similar to ABCL for comparison